It is made available under a CC-BY 4.0 International license .

1 2 3	Accuracy of self-reported HIV testing history and awareness of HIV-positive status among people living with HIV in four Sub-Saharan African countries
4 5 6	Yiqing Xia1, Rachael M Milwid1, Arnaud Godin1, Marie-Claude Boily2, Leigh F Johnson3, Kimberly Marsh4, Jeffrey W Eaton2, Mathieu Maheu-Giroux1
7	Affiliations:
8	(1) Department of Epidemiology, Biostatistics, and Occupational Health, School of
9	Population and Global Health, McGill University, Montréal, QC, Canada
10	(2) MRC Centre for Global Infectious Disease Analysis, School of Public Health,
11	Imperial College London, London, United Kingdom
12	(3) Centre for Infectious Disease Epidemiology and Research, University of Cape
13	Town, Cape Town, South Africa
14	(4) Strategic Information Department, Joint UN Programme on HIV/AIDS
15	(UNAIDS), Geneva, Switzerland
16	

- 17 Correspondence:
- 18 Mathieu Maheu-Giroux
- 19 mathieu.maheu-giroux@mcgill.ca
- 20

It is made available under a CC-BY 4.0 International license .

22 Abstract

Background: In many countries in Sub-Saharan Africa, self-reported HIV testing history
and awareness of HIV-positive status from household surveys are used to estimate the
percentage of people living with HIV (PLHIV) who know their HIV status. Despite
widespread use, there is limited empirical information on the sensitivity of those selfreports, which can be affected by non-disclosure.

Methods: Bayesian latent class models were used to estimate the sensitivity of selfreported HIV testing history and awareness of HIV-positive status in four *Population- based HIV Impact Assessment* surveys in Eswatini, Malawi, Tanzania, and Zambia.
Antiretroviral (ARV) metabolites biomarkers were used to identify persons on treatment
who did not accurately report their status. For those without ARV biomarkers, the
pooled estimate of non-disclosure among untreated persons was 1.48 higher than those
on treatment.

Results: Among PLHIV, the sensitivity of self-reported HIV testing history ranged 96% to 99% across surveys. Sensitivity of self-reported awareness of HIV status varied from 91% to 97%. Non-disclosure was generally higher among men and those aged 15-24 years. Adjustments for imperfect sensitivity did not substantially influence estimates of of PLHIV ever tested (difference <4%) but the proportion of PLHIV aware of their HIV-positive status was higher than the unadjusted proportion (difference <8%).</p>

41 Conclusions: Self-reported HIV testing histories in four Eastern and Southern African
 42 countries are generally robust although adjustment for non-disclosure increases

- 43 estimated awareness of status. These findings can contribute to further refinements in
- 44 methods for monitoring progress along the HIV testing and treatment cascade.
- 45 Keywords: Sensitivity; Bayesian latent class; self-report; testing behaviors; HIV
- 46 disclosure; HIV/AIDS

It is made available under a CC-BY 4.0 International license .

48 **INTRODUCTION**

49 Monitoring the HIV treatment and care cascade is central to the *Joint United Nations* 50 Programme on HIV/AIDS' (UNAIDS) objective of ending the AIDS epidemic as a public 51 health risk by 2030 (1). Routine tracking of population-level progress towards the UNAIDS' 2020 90-90-90 and 2030 95-95-95 diagnostic, treatment, and viral load 52 53 suppression targets can guide public health initiatives and improve programmatic 54 efficiencies (2). However, estimating progress towards the first pillar of the targets -the 55 percentage of people living with HIV (PLHIV) who know their HIV status- is challenging. 56 In sub-Saharan Africa (SSA), where 67% of the 38 million PLHIV were estimated to 57 reside in 2019 (3), measures of awareness are typically constructed from data about 58 self-reported HIV testing behaviour or reported directly from nationally representative 59 household surveys (4-8).

Consideration of the potential for measurement bias is needed when interpreting self-60 reported survey data. Studies have shown that self-reporting about sensitive 61 62 information, such as an individual's HIV testing history and HIV status, could be affected 63 by non-disclosure (6, 9, 10). For example, inconsistencies have been documented in 64 Kenya and Malawi between an individual's self-reported data and biomarkers for 65 metabolites of antiretrovirals (ARVs) and viral load suppression (5, 10). While previous 66 studies have sought to validate the accuracy of self-reported HIV status (10-12), 67 analyzing recent data on both non-disclosure of self-reported HIV testing history and HIV status among PLHIV is key to improving the validity of these estimates. 68

It is made available under a CC-BY 4.0 International license .

69 Surveys that collect both self-reported information and ARV biomarkers can be used to

assess the accuracy of self-reported HIV testing histories and HIV awareness status. In

this study, Bayesian latent class models are used to estimate the sensitivity of self-

reported HIV testing history and awareness of HIV status among PLHIV based on the

73 presence of detectable ARVs (13).

74 Methods

75 Study population

76 The Population-based HIV Impact Assessment (PHIA) surveys are nationally

77 representative multistage household-based surveys designed to provide population-

78 level information on the burden of HIV disease and to document the progress of HIV

79 programs (14-17). All four PHIA surveys with available microdata on PLHIV aged 15+

- 80 years of age were included in our analysis: Swaziland (Eswatini) HIV Incidence
- 81 Measurement Survey 2 (2015-2016), Malawi PHIA (2015-2016), Tanzania HIV Impact
- 82 Survey (2016-2017), and Zambia PHIA (2016).

83 Self-reports and antiretroviral (ARV) status

84 Participants who reported having ever received the results of any HIV test were

classified as ever tested and received results (hereafter referred to as "ever tested"; see

86 Table S1). Participants who reported having received a positive test result after any HIV

- 87 test, were classified as *aware of HIV-positive status*. The specific laboratory algorithms
- used to detect ARVs varied across surveys, although all were analyzed in the same

It is made available under a CC-BY 4.0 International license .

- 89 laboratory, and included drugs in the nationally recommended first- and second- line
- 90 regimens: efavirenz, lopinavir, and nevirapine (14-17).

91 Bayesian latent class models

- 92 Bayesian latent class models (18) were used to quantify the sensitivity of both self-
- 93 reported HIV testing history and HIV status awareness among PLHIV. Cross-tabulations
- 94 of self-reports with ARV biomarkers provide empirical information on their sensitivity
- among those with detectable ARVs (Figure 1A).

With regard to participants with detectable ARVs, we assumed that: (1) they had been
tested for HIV, received their results, and were aware of their status; and (2) there were
no false positives in the detection of ARV metabolites, self-reported HIV testing history,

99 or awareness of HIV status.

100 As ARV metabolite data only provide information about the sensitivity of self-reports among participants on ARVs, the ratio of non-disclosure for PLHIV without detectable 101 ARVs versus those with detectable ARVs was given a log-normal prior distribution with 102 103 a mean of log(1.48) (standard error: 4) to estimate the sensitivity of self-reports for 104 people without detectable ARVs. This prior was elicited by reviewing available studies 105 an meta-analyzing the evidence. The pooling of two studies conducted in rural 106 Mozambigue and Malawi (19, 20) suggests that people not receiving ARVs are 1.48 107 more likely to not disclose their diagnosis. Additional analyses were conducted to 108 investigate the influence of this prior on our results. Equations and prior distributions are 109 presented in the Supplementary Materials (Table S2 and Text S1).

It is made available	e under a CC-BY	4.0 International	license
----------------------	-----------------	-------------------	---------

110 Given known blases in self-reported estimates of HIV status awareness, analysis	ts often
---	----------

- 111 manually reclassify individuals not aware of their status but with detectable ARVs -as in
- 112 published PHIA reports. Most surveys, however, do not collect ARV biomarkers and
- only rely on self-reported information. To examine the impact of this partial adjustment,
- we compared the unadjusted, ARV-reclassified (as in PHIA reports), and Bayesian-
- adjusted estimates of PLHIV aware.
- 116 Models were run separately for each country and for subgroup analyses (i.e. age, sex,
- 117 urban/rural and socio-economic status). Bayesian hierarchical models using Markov
- 118 Chain Monte Carlo (MCMC), implemented through the JAGS software (21) and the
- *rjags* packages, were used to approximate the posterior densities (22, 23).

120 Ethics

- 121 Ethics approval for secondary data analyses was obtained from McGill University's
- 122 Faculty of Medicine Institutional Review Board (A10-E72-17B).

123

It is made available under a CC-BY 4.0 International license .

Detection of **ARV** metabolites **Observed data** ARV+ ARV-А Definitions for A to H Self-reported ever tested Ever A+B C+D (Unobserved) Self-report **ARV Status** for HIV and received **Gold Standard** E+F G+H Never results ARV+ Ever Ever Α В ARV+ Never Ever С Ever ARV-Ever D Never ARV-Ever В Е ARV+ Ever Never (Unobserved) Gold standard of ever tested and received results F Never ARV+ Never **Unobserved data structure** Ever tested Never tested G Ever ARV-Never ARV -ARV + ARV + ARV н ARV-Never Never Self-reported ever Ever A С B=0 D tested for HIV and F=0 G Never Е Η received results

Figure 1. Observed and unobserved data structure of self-reported *ever tested and received results*, and antiretroviral (ARV) metabolites status. Definitions for cells A to H are listed in the table. As it was assumed that participants with detectable ARV must have been tested, cells B and F are *de facto* equal to zero. The same technique was applied to the self-reported awareness of HIV status and was applied to all four Sub-Saharan African countries.

133

125

It is made available under a CC-BY 4.0 International license .

134 Results

- 135 Overall, 3,003 PLHIV from Eswatini, 2,227 PLHIV from Malawi, 1,831 PLHIV from
- 136 Tanzania, and 2,467 PLHIV from Zambia were included in the analyses. In all countries,
- a high fraction of PLHIV reported having ever been tested and the proportion of PLHIV
- reporting being aware of their status ranged from 68.0% in Tanzania to 86.5% in
- 139 Eswatini. The proportion of PLHIV with detectable ARV metabolites was highest in
- 140 Eswatini (76.0%), followed by Malawi (68.1%), Zambia (61.5%), and Tanzania (53.9%).

141 Sensitivity of self-report

142 Self-reported testing history

- 143 Among participants with detectable ARVs, the estimated sensitivity was highest in
- 144 Eswatini at 99.5% (95% credible interval [95%Crl]: 99.2-99.8%), followed by Malawi
- 145 (98.2%; 97.5-98.8%), Zambia (97.4%; 96.5-98.1%), and Tanzania (96.6%; 95.3-97.6%)
- 146 (Figure 2). For people without ARV metabolites, the estimated sensitivity was 2.4%
- points (0.1-11.4%) lower than those with detectable ARVs in Tanzania. The differences
- 148 were smaller elsewhere. Detailed values can be found in *Supplementary Table 3*.
- 149 Self-reported awareness of HIV status
- 150 The sensitivity of self-reported awareness of HIV-positive status among participants with
- 151 ARV metabolites was 97.4% (96.7-98.0%) in Eswatini, 94.2% (93.0-95.4%) in Malawi,
- 152 92.3% (90.5-93.8%) in Tanzania, and 91.6% (90.1-92.9%) in Zambia (Figure 2A). The
- 153 estimated differences in sensitivity between PLHIV with ARV metabolites and those

It is made available under a CC-BY 4.0 International license .

- 154 without were 1.8% points (0.1-8.5%), 4.2% points (0.2-19.6%), 5.7% points (0.3-26.7%)
- and 6.2% points (0.3-29.0%) in Eswatini, Malawi, Tanzania, and Zambia respectively.

156 Differences by gender, age, rural/urban, and socioeconomic status

- 157 Among participants with detectable ARVs, women had 0.9-2.4% points higher
- sensitivities of self-reported HIV testing history and HIV status awareness than men
- 159 (Figure 2B). The estimated sensitivities were the lowest at age 15-24 years (94.7-97.2%
- 160 for HIV testing history and 83.9-91.9% for HIV status awareness) in all of the countries
- 161 (Figure 2C). Participants residing in urban and rural areas had similar sensitivities
- 162 (*Figure S1A*) and variations by socio-economic status (SES) were also small (*Figure*
- 163 S1B and Figure S2).

164 Adjusted proportion of PLHIV ever tested and PLHIV aware of their status

Adjusting for imperfect sensitivity influenced the estimates of the self-reported
proportion ever tested for HIV less (largest difference between the adjusted and the
self-reports was 3.9% points in Tanzania) than the estimates of self-reported proportion
of PLHIV aware of their status (largest difference was 7.2% points in Zambia) (Figure
2D). Results were less affected by the assumed non-disclosure ratio for PLHIV without
detectable ARV metabolites when antiretroviral therapy (ART) coverage is high (*Figure*S3).

It is made available under a CC-BY 4.0 International license .



Figure 2. Marginal posterior medians and 95% credible intervals for selected outcomes. Sensitivity of self-reported ever tested and received results, and awareness of HIV-positive status among people living with HIV (PLHIV) by: (A) antiretroviral (ARV) metabolites status, (B) gender (ARV+), and (C) age groups (ARV+). Panel D portrays the overall proportion of PLHIV ever tested who received results and the awareness of HIV-positive status (self-reported vs. adjusted ARV metabolites status vs. fully adjusted).

It is made available under a CC-BY 4.0 International license .

174 Discussion

175 Self-reported information on HIV testing and diagnosis are primary data sources used to 176 monitor trends in the HIV treatment and care continuum (2, 9). These same data have 177 also been proposed to estimate cross-sectional HIV incidence (24). In this study, we leveraged ARV biomarkers from four household representative surveys in Eswatini, 178 Malawi, Tanzania and Zambia to estimate the sensitivity of self-reported HIV testing 179 180 history and awareness of HIV status among PLHIV. We found that self-reports of HIV 181 testing history have a high sensitivity (>96%) among PLHIV with detectable ARVs 182 across these settings. Self-reported awareness of HIV status had a marginally lower 183 sensitivity (>91%) in these same countries.

184 Subgroup analyses revealed nonnegligible lower sensitivities of both self-reported HIV 185 testing history and awareness of status among male PLHIV and those aged 15-24 years which could result from social desirability bias (25). Additionally, differences in survey 186 187 instruments could result in higher sensitivities for women. For example, in the PHIA 188 survey, women are asked about HIV testing up to 4 times (before pregnancy, during 189 pregnancy, during labor, and at their last HIV test), while men were asked only once. As 190 women were classified based on the positive response to any of the 4 questions, this 191 increased the probability of women disclosing their true status.

In this study, we estimated the sensitivity of the self-reports alone but when ARV
biomarkers are available, presentation of cascade results from the surveys usually
adjust these self-reports by reclassifying PLHIV that do not disclose their status but for
which ARV metabolites are detected as "aware". We have found that this partial

It is made available under a CC-BY 4.0 International license .

adjustment may be insufficient, especially if ART coverage is low in the surveyed
population and the ratio of non-disclosure among those not on ART is high (26-29). To
accurately estimate awareness of status, results must also be adjusted for nondisclosure among PLHIV with undetectable ARVs.

Our results need to be interpreted considering certain study limitations. First, only four 200 201 PHIA surveys have publicly available micro-data, none of which are located in the West 202 and Central African regions, where non-disclosure could be higher (30). The PHIA 203 included here had some of the lowest levels of non-disclosure of these reviewed studies 204 suggesting that other settings could have lower sensitivities. Second, our study design 205 limited our assessment of the sensitivity of testing history to PLHIV, and findings should 206 not be extrapolated to people not living with HIV. Third, it is not possible to empirically 207 validate the sensitivity of self-reports among PLHIV without ARV metabolites. As such, 208 we had to use information from two previous studies that used medical records to inform 209 the non-disclosure ratio. Results could be sensitive to this non-disclosure ratio but the 210 high ART coverage in the four countries mitigates this influence (*Figure S3*). Finally, the 211 specificity of self-reports was assumed to be 100% which could lead to overestimating 212 the proportion of PLHIV ever tested / aware of HIV-positive status. However, previous study has shown a high specificity of self-reported HIV testing results (11) implying that 213 214 this assumption will likely have little impact on the outcomes.

Strengths of this study include the use of standardized survey and laboratory data (i.e.
detection of ARV metabolites). Second, the Bayesian latent class models propagate
uncertainty to our results by assuming prior distributions and generating posterior

It is made available under a CC-BY 4.0 International license .

credible intervals. Finally, we examined sex, age, urban/rural, and SES differences in
the sensitivity of self-reports.

In conclusion, self-reported HIV testing histories have high sensitivities in the four
countries examined but self-reported awareness of HIV status are lower. Whenever
available, ARV biomarkers data can be used to adjust self-reports but such adjustments
may still underestimate diagnosis coverage, especially if ART coverage is low in that
population. Future research should extend this work in other regions and populations.

225 Acknowledgements

226 We acknowledge funding from the Steinberg Fund for Interdisciplinary Global Health 227 Research (McGill University). MMG's research program is funded through a Canada 228 Research Chair (Tier 2) in Population Health Modeling. JWE acknowledges funding 229 from the Bill and Melinda Gates Foundation and UNAIDS. MCB acknowledge funding 230 from MRC Centre for Global Infectious Disease Analysis (MRC GIDA, MR/R015600/1). 231 This award is jointly funded by the UK Medical Research Council (MRC) and the UK 232 Department for International Development (DFID) under the MRC/DFID Concordat 233 agreement and is also part of the EDCTP2 programme supported by the European 234 Union. LJ acknowledges funding from UNAIDS.

236 **REFERENCES**

237 1. UNAIDS. 90 - 90 - 90: an ambitious treatment target to help end the AIDS epidemic. 238 Geneva: Joint United Nationas Programme on HIV/AIDS (UNAIDS); 2014. 239 Rentsch CT, Georges Reniers, Richard Machemba, Emma Slaymaker, Milly Marston, 2. 240 Alison Wringe, et al. Non-disclosure of HIV testing history in population-based surveys: 241 implications for estimating a UNAIDS 90-90-90 target. Global Health Action. 242 2018;11(1):1553470. 243 UNAIDS. UNAIDS data 2019. 3. 244 Sarah Staveteig SW, Sara K. Head, Sarah E.K. Bradley, Erica Nybro. Demographic patterns 4. 245 of HIV testing uptake in sub-Saharan Africa: DHS comparative reports 30. Calverton: ICF Macro; 246 2013. 247 5. Kim AA, Mukui I, Young PW, Mirjahangir J, Mwanyumba S, Wamicwe J, et al. 248 Undisclosed HIV infection and antiretroviral therapy use in the Kenya AIDS indicator survey 249 2012: relevance to national targets for HIV diagnosis and treatment. AIDS. 2016;30(17):2685-250 95. 251 Anand A, Shiraishi RW, Bunnell RE, Jacobs K, Solehdin N, Abdul-Quader AS, et al. 6. 252 Knowledge of HIV status, sexual risk behaviors and contraceptive need among people living 253 with HIV in Kenya and Malawi. AIDS. 2009;23(12):1565-73. 254 Cherutich P, Kaiser R, Galbraith J, Williamson J, Shiraishi RW, Ngare C, et al. Lack of 7. 255 knowledge of HIV status a major barrier to HIV prevention, care and treatment efforts in Kenya: 256 results from a nationally representative study. PLoS One. 2012;7(5):e36797. 257 8. Maheu-Giroux M, Marsh K, Doyle CM, Godin A, Laniece Delaunay C, Johnson LF, et al. 258 National HIV testing and diagnosis coverage in sub-Saharan Africa: a new modeling tool for 259 estimating the 'first 90' from program and survey data. AIDS. 2019;33 Suppl 3:S255-S69. 260 Organization WH. Consolidated strategic information guidelines for HIV in the health 9. 261 sector. Geneva: World Health Organization; 2015. 262 Fishel JD BB, Kishor S. Validity of data on self- reported HIV status and implications for 10. 263 measurement of ARV coverage in Malawi. DHS Working Paper No. 81. Calverton, Maryland, 264 USA: ICF International; 2012. 265 Fisher DG, Reynolds GL, Jaffe A, Johnson ME. Reliability, sensitivity and specificity of self-11. 266 report of HIV test results. AIDS Care. 2007;19(5):692-6. 267 12. Rohr JK, Xavier Gomez-Olive F, Rosenberg M, Manne-Goehler J, Geldsetzer P, Wagner 268 RG, et al. Performance of self-reported HIV status in determining true HIV status among older 269 adults in rural South Africa: a validation study. J Int AIDS Soc. 2017;20(1):21691. 270 Goncalves L, Subtil A, de Oliveira MR, do Rosario V, Lee PW, Shaio MF. Bayesian Latent 13. 271 Class Models in malaria diagnosis. PLoS One. 2012;7(7):e40633. 272 Malawi population-based HIV impact assessment (MPHIA) 2015-2016 data use manual 14. supplement. New York, NY; December 2018. 273 274 Swaziland HIV incidence measurement survey 2 (SHIMS2) 2016-2017 data use manual 15. 275 supplement. New York, NY; April 2019. 276 Tanzania HIV impact survey (THIS) 2016-2017 data use manual supplement. New York, 16. 277 NY; December 2018.

278 17. Zambia population-based HIV impact assessment (ZAMPHIA) 2016-2017 data use 279 manual supplement. New York, NY; February 2019. 280 18. Joseph L, Gyorkos TW, Coupal L. Bayesian estimation of disease prevalence and the 281 parameters of diagnostic tests in the absence of a gold standard. Am J Epidemiol. 282 1995;141(3):263-72. 283 Fuente-Soro L, Lopez-Varela E, Augusto O, Sacoor C, Nhacolo A, Honwana N, et al. 19. Monitoring progress towards the first UNAIDS target: understanding the impact of people living 284 285 with HIV who re-test during HIV-testing campaigns in rural Mozambique. J Int AIDS Soc. 286 2018;21(4):e25095. 287 Chasimpha SJD, McLean EM, Dube A, McCormack V, Dos-Santos-Silva I, Glynn JR. 20. Assessing the validity of and factors that influence accurate self-reporting of HIV status after 288 289 testing: a population-based study. AIDS. 2020;34(6):931-41. 290 Plummer M. editor JAGS: A Program for Analysis of Bayesian Graphical Models Using 21. 291 Gibbs Sampling. Proceedings of the 3rd International Workshop on Distributed Statistical 292 Computing (DSC 2003); 2003 March 20–22; Vienna, Austria. 293 22. Alan E. Gelfand AFMS. Sampling-based approaches to calculating marginal densities. 294 Journal of the American Statistical Association. 1990;85(410):398-409. 295 23. Alan E. Gelfand SEH, Amy Racine-Poon, Adrian F. M. Smith. Illustration of Bayesian 296 inference in normal data models using Gibbs sampling. Journal of the American Statistical 297 Association. 1990;85(412):972-85. 298 24. Fellows IE, Shiraishi RW, Cherutich P, Achia T, Young PW, Kim AA. A new method for 299 estimating HIV incidence from a single cross-sectional survey. PLoS One. 2020;15(8):e0237221. 300 Mooney AC, Campbell CK, Ratlhagana MJ, Grignon JS, Mazibuko S, Agnew E, et al. 25. 301 Beyond social desirability bias: investigating inconsistencies in self-reported HIV testing and 302 treatment behaviors among HIV-positive adults in North West province, South Africa. AIDS 303 Behav. 2018;22(7):2368-79. 304 Eswatini GotKo. Swaziland HIV incidence measurement survey 2 (SHIMS2) 2016-2017. 26. Final report. Mbabane: Government of the Kingdom of Eswatini; April 2019. 305 306 27. Ministry of Health M. Malawi population-based HIV impact assessment (MPHIA) 2015-2016: Final report. Lilongwe: Ministry of Health; October 2018. 307 308 Tanzania Commission for AIDS (TACAIDS), (ZAC) ZAC. Tanzania HIV impact survey (THIS) 28. 309 2016-2017: Final report. Dar es Salaam: Tanzania; December 2018. 310 Ministry of Health Z. Zambia population-based HIV impact assessment (ZAMPHIA) 2016: 29. 311 Final report. Lusaka: Ministry of Health; February 2019. 312 30. Eba PM. HIV-specific legislation in sub-Saharan Africa: A comprehensive human rights 313 analysis. African Human Rights Law Journal. 2015;15:224-62. 314